Selenium Blood Test: What It Actually Measures and Why It Matters

What the test actually measures

A serum or plasma selenium test is a total-selenium measurement, not a direct readout of any single enzyme. It captures selenium bound to selenoprotein P (SELENOP), glutathione peroxidase 3 (GPx3), and albumin. SELENOP alone accounts for roughly half to two-thirds of plasma selenium in people who are adequately nourished (Burk & Hill, 2005).

A single draw reflects selenium status at that moment, not intracellular stores or long-term intake. Whole blood or toenail selenium testing exists as an alternative that better reflects intake over weeks to months, because red blood cells pick up selenium during formation and hold it for their roughly 120-day lifespan, but these tests are ordered far less often than serum selenium.

Selenium's biological work happens through selenocysteine, sometimes called the 21st amino acid, which is built into at least two dozen human selenoproteins (Rayman, 2012). Three families matter most in clinical practice: glutathione peroxidases (antioxidant defense), iodothyronine deiodinases (thyroid hormone activation and inactivation), and thioredoxin reductases (redox regulation and DNA repair). When selenium is insufficient, these enzyme systems lose catalytic capacity in a dose-related way rather than failing all at once.

Serum selenium concentrations between roughly 70 and 150 mcg/L do correlate reasonably well with selenoprotein expression in population studies, which is part of why the reference range was set where it is (Thomson, 2004).

A serum selenium test measures total circulating selenium, mostly carried on selenoprotein P and glutathione peroxidase 3, reported in mcg/L. Most U.S. laboratories use a reference range of 70 to 150 mcg/L, but glutathione peroxidase activity tends to plateau closer to 90 to 100 mcg/L and selenoprotein P saturation closer to 110 to 125 mcg/L, so a result inside the reference range is not automatically a result at full enzymatic capacity (Thomson, 2004; Hurst et al., 2010). Values below 70 mcg/L are conventionally called deficient and values above 400 mcg/L indicate selenosis; the clinically relevant question is usually where a result sits between those two boundaries relative to why the test was ordered.

What counts as normal, optimal, or deficient

Most U.S. reference laboratories report 70 to 150 mcg/L as the serum selenium reference range. That range comes from population studies linking serum selenium to glutathione peroxidase activity and selenoprotein P saturation, not from an arbitrary cutoff (Hurst et al., 2010).

"Normal" and "optimal" are not the same thing here. A result of 72 mcg/L sits inside the reference range, but glutathione peroxidase activity at that level may still be well below its maximum. Guideline discussion around thyroid disease has favored serum concentrations of roughly 100 mcg/L or higher when the goal is optimizing selenoprotein activity rather than simply avoiding deficiency (Kahaly et al., 2018 European Thyroid Association guideline). Many endocrinology practices use 100 to 130 mcg/L as a working target for thyroid patients specifically, though this is a practice pattern rather than a single universally adopted cutoff.

Selenium enters the food chain through soil, and soil selenium content varies enormously by region. Populations in low-selenium regions, including parts of China, historically Finland before the country began fortifying agricultural fertilizer, and parts of New Zealand, show measurably lower serum selenium than populations on selenium-rich soils. Modeling work published in the Proceedings of the National Academy of Sciences estimated that a substantial share of the global population lives in areas with marginal or low soil selenium, and projected that this risk would expand under future climate scenarios (Jones et al., 2017). That is a model-derived estimate about soil and climate, not a direct measured prevalence survey of blood selenium, so treat any specific global head-count with some caution.

In the United States, selenium intake is generally adequate because agricultural soils in parts of the country are comparatively selenium-rich, and national surveys tend to show serum selenium clustering in the upper half of the reference range. Individual results still vary widely with diet, geography, and gut absorption, so this population pattern should not be used to assume any one person's status.

What a low result means, and how worried to be

Serum selenium below 70 mcg/L is conventionally called deficient. Results between 70 and 85 mcg/L sit in a suboptimal zone where selenoprotein function may be measurably reduced without overt clinical disease.

Severe deficiency, generally below 30 mcg/L, is associated with two named conditions that are rare in the United States but still seen in parts of rural China and Tibet. Keshan disease is a cardiomyopathy that results from combined selenium deficiency and coxsackievirus B infection (Beck et al., 2003). Kashin-Beck disease is an osteoarthropathy affecting cartilage and growth plates in children and adolescents.

More relevant to routine U.S. practice, moderate deficiency (roughly 40 to 70 mcg/L) can impair thyroid hormone metabolism, because the type 2 deiodinase (DIO2) that converts T4 to active T3 requires selenocysteine at its active site. A prospective Chinese cohort study (n=1,900) reported that participants in the lowest quartile of serum selenium had a higher rate of subclinical hypothyroidism than those in the highest quartile (reported odds ratio 1.62, 95% CI 1.12 to 2.34) (Wu et al., 2015). This is a single observational cohort from a specific population; it supports an association worth investigating in a patient with unexplained thyroid findings, not a universal dose-response rule.

A framework for deciding what to do with a selenium result

The number on the lab report only becomes useful once it is paired with why the test was ordered and what else is going on with the patient. The table below is a starting framework, not a substitute for clinical judgment.

A few modifiers change how much weight to put on any single number:

• Sample quality. A hemolyzed sample can falsely elevate results because red blood cells carry selenium-dependent GPx1. A borderline-high result from a hemolyzed draw should be repeated before acting on it.
• Recent supplement timing. A result drawn soon after a supplement dose can run higher than steady-state status. Ask when the last dose was taken relative to the draw.
• Acute illness. Selenium transport proteins behave like other negative acute-phase markers in some contexts, so a value drawn during an acute infection or inflammatory flare may understate baseline status (Rayman, 2012). Where possible, retest once the acute illness has resolved before concluding someone is chronically deficient.
• Dual iodine-selenium deficiency. In a patient with signs of both selenium and iodine deficiency, correcting selenium alone can increase DIO2-driven degradation of T4 and worsen hypothyroidism. Clinical discussion of this mechanism generally favors addressing iodine status first, or at least concurrently, rather than treating selenium in isolation (Schomburg, 2012).
• Bariatric surgery, IBD, celiac disease, or long-term parenteral nutrition. Any of these raises the pretest suspicion for true deficiency and lowers the threshold to test and to treat.

What a high result means, and whether supplementing is risky

Serum selenium above 150 mcg/L deserves a look at where the selenium is coming from, usually supplementation. Values above 400 mcg/L indicate frank selenosis, and the tolerable upper intake level set by the Institute of Medicine is 400 mcg per day from all sources combined (IOM, 2000).

Early signs of excess include garlic-like breath (from exhaled dimethyl selenide), brittle nails with horizontal streaking, and hair loss. These are generally reversible once intake is reduced. More severe, sustained excess can cause peripheral neuropathy, fatigue, irritability, and gastrointestinal symptoms.

The Nutritional Prevention of Cancer (NPC) trial was originally designed to test selenium supplementation (200 mcg/day as selenized yeast) against skin cancer recurrence. A post-hoc analysis found an increased risk of type 2 diabetes among participants with higher baseline selenium who received additional supplementation, reported as roughly a 55% relative increase in risk (Stranges et al., 2007). The larger SELECT trial (n=35,533) later found that 200 mcg/day of selenomethionine did not reduce prostate cancer risk (Lippman et al., 2009). Both findings are post-hoc or secondary analyses of trials designed around cancer endpoints, not dedicated diabetes-outcome trials, which is a real limitation on how strongly the diabetes signal should be interpreted, but it is consistent enough across two large randomized trials that it changed clinical guidance.

That shift shows up in endocrine guidance that generally advises against routine selenium supplementation in people who are already selenium-replete, given the absence of demonstrated benefit in that group alongside a signal of possible metabolic risk in trial data (Garber et al., 2012, AACE/ATA hypothyroidism guideline).

Should you treat with diet, supplements, or both?

Correcting deficiency depends on how low the level is, what is causing it, and whether malabsorption is in play.

Food sources provide selenium mainly as selenomethionine and selenocysteine, organic forms with high bioavailability (commonly cited around 80 to 90 percent absorption). Brazil nuts are the most concentrated common food source, though content varies with the soil the tree grew in. A New Zealand randomized trial (n=59) found that daily Brazil nut intake raised plasma glutathione peroxidase activity from baseline over 12 weeks (Thomson et al., 2008); exact serum-selenium increases will vary by individual and by the nuts' actual selenium content, which is not standardized. Other selenium-rich foods include tuna, halibut, sardines, turkey, and eggs, per the NIH Office of Dietary Supplements fact sheet (ODS).

When supplementation is used, two forms are common:

• Selenomethionine, an organic form that incorporates nonspecifically into body proteins in place of methionine, building a tissue reservoir. This is the form used in the NPC and SELECT trials.
• Sodium selenite, an inorganic form metabolized more directly to selenide for selenoprotein synthesis, without the same nonspecific tissue storage. Some clinicians prefer it partly to avoid excessive accumulation.

Typical repletion dosing in clinical use runs 100 to 200 mcg/day for 8 to 12 weeks, with a repeat serum test to confirm the target was reached rather than assuming it based on dose alone. Selenium researcher Margaret Rayman has written that the margin between selenium deficiency and toxicity is comparatively narrow relative to many other trace elements, which is part of the rationale for retesting during supplementation rather than continuing a fixed dose indefinitely without follow-up (Rayman, 2020).

For malabsorption that cannot be corrected through diet, parenteral selenium is a standard component of trace element formulations used in long-term parenteral nutrition, per ASPEN's position paper on trace element products (Vanek et al., 2012). Dosing in that setting is an infusion-therapy decision made by the managing team, not something to self-direct.

Why selenium matters for thyroid function

The thyroid gland holds more selenium per gram of tissue than any other organ, which is a clue to how central selenium is to thyroid biology rather than an incidental fact.

Three deiodinase enzymes govern peripheral thyroid hormone metabolism, and all three are selenoproteins. DIO1 and DIO2 convert T4 to active T3. DIO3 converts T4 to inactive reverse T3 and degrades T3 to T2 (Schomburg, 2012).

The clinical link is clearest in autoimmune thyroid disease. A randomized controlled trial (n=70) found that 200 mcg/day of sodium selenite for three months reduced thyroid peroxidase antibody (TPO-Ab) titers, compared with an increase in the placebo group (Gärtner et al., 2002). Later trials have generally replicated an antibody-lowering effect, with effect sizes that vary by study. What has not been consistently shown is that lowering TPO-Ab titers by itself changes how a patient feels or how their thyroid function trends over time; the European Thyroid Association's guideline discussion notes that antibody reduction is a reasonably consistent finding across trials while evidence for patient-relevant outcomes is more limited (Kahaly et al., 2018). That guideline does support considering selenium supplementation (around 200 mcg/day for about six months) specifically in mild Graves' orbitopathy, based in part on a European multicenter trial (EUGOGO, n=159) that reported improved quality-of-life scores and slower progression in the selenium group. The guideline stops short of a blanket recommendation for Hashimoto's thyroiditis.

For a patient with both suboptimal selenium and thyroid dysfunction, checking selenium before escalating a levothyroxine dose can be informative: a T4-to-T3 conversion problem driven by selenium insufficiency will not necessarily respond to more levothyroxine alone. This is a reasonable diagnostic consideration, not a substitute for standard thyroid function testing and TSH-based dose titration.

Selenium as an antioxidant marker: how much does it add?

Selenium's antioxidant role runs mainly through the glutathione peroxidase family. GPx1 (cytosolic), GPx2 (gastrointestinal), GPx3 (plasma), and GPx4 (phospholipid-associated) all use selenium at their catalytic sites to reduce hydrogen peroxide and lipid hydroperoxides (Rayman, 2012).

GPx3, the isoform most relevant to what a serum selenium test indirectly reflects, protects circulating lipoproteins from oxidative modification. A nested case-control analysis within the EPIC-Heidelberg cohort (474 cases, 474 controls) found a higher colorectal cancer risk in the lowest quartile of serum selenium after adjustment for confounders (odds ratio 1.39, 95% CI 1.01 to 1.92) (Hughes et al., 2015). This is an observational association from one cohort, useful as a piece of the broader picture rather than a basis for using selenium as a cancer-screening tool.

The thioredoxin reductase pathway, the other major selenoprotein antioxidant system, regenerates oxidized thioredoxin, which in turn reduces oxidized proteins and helps regulate redox-sensitive transcription factors such as NF-kB and AP-1, linking selenium status to inflammatory signaling at a mechanistic level. Clinicians ordering selenium as part of an oxidative-stress workup often pair it with markers like glutathione, 8-OHdG, or F2-isoprostanes rather than relying on selenium alone.

Who actually needs this test, and how often

Selenium is not part of routine wellness panels. It is a targeted test ordered when there is a clinical reason to suspect deficiency or excess. Reasonable indications include:

• Thyroid dysfunction that is not responding as expected to standard levothyroxine dosing, particularly suspected impaired T4-to-T3 conversion
• Autoimmune thyroid disease, especially when selenium supplementation is being considered as adjunctive therapy
• Post-bariatric surgery monitoring
• Chronic malabsorption from celiac disease, Crohn's disease, short bowel syndrome, or chronic pancreatitis
• Long-term parenteral nutrition, monitored per ASPEN guidance (Vanek et al., 2012)
• Unexplained cardiomyopathy with other risk factors for nutritional deficiency
• Male infertility workup with abnormal semen morphology or motility
• Monitoring in someone taking high-dose selenium supplements, to screen for excess

Recheck intervals depend on why the test was ordered in the first place. For repletion monitoring, retesting 8 to 12 weeks after starting supplementation is a common pattern. For ongoing monitoring in bariatric or malabsorption patients, roughly every 6 to 12 months is typical in clinical practice, with dialysis and parenteral nutrition patients often monitored more frequently per their nutrition support team's protocol.

No special preparation is required, and fasting is not necessary. A clean, non-hemolyzed sample matters more than fasting status, since hemolysis can artificially raise the measured value.

Other things that change the interpretation

Selenium metabolism intersects with iodine, vitamin E, and a few medications in ways that matter for interpretation, not just biochemistry trivia.

Iodine. Selenium and iodine deficiency together worsen hypothyroidism more than either alone. Correcting selenium before iodine in a severely iodine-deficient population can, mechanistically, increase DIO2-driven T4 degradation and worsen hypothyroidism rather than help it (Schomburg, 2012). This is mainly relevant in populations with genuine iodine deficiency, which is uncommon but not absent in the U.S.

Vitamin E. Vitamin E scavenges lipid peroxyl radicals in cell membranes while GPx4 reduces the resulting lipid hydroperoxides, so the two nutrients work as a linked antioxidant system. Animal data show that vitamin E deficiency can accelerate the clinical manifestations of selenium deficiency and vice versa (Rayman, 2012).

Medications. Proton pump inhibitors may reduce selenium absorption by raising gastric pH, and cisplatin-based chemotherapy has been associated with selenium depletion. In a patient on long-term PPI therapy with a suboptimal result, it is worth assessing diet before attributing the finding to the medication alone, since the two explanations are not mutually exclusive and often overlap.

A serum selenium of 55 mcg/L in someone with a history of Roux-en-Y gastric bypass on chronic PPI therapy is a different clinical story than the same number in a healthy vegan athlete who simply does not eat selenium-rich foods often. The number is identical; the workup and the urgency are not.

What is established, what is plausible, and what is not

Established: Selenium is required for selenocysteine-dependent enzymes, including glutathione peroxidases and the deiodinases that regulate thyroid hormone activity. Severe deficiency causes Keshan disease and Kashin-Beck disease. Chronic intake above 400 mcg/day produces a recognizable toxicity syndrome. Selenium supplementation reduces TPO antibody titers in autoimmune thyroiditis in randomized trials, and a European guideline supports considering supplementation specifically for mild Graves' orbitopathy.

Plausible but not proven at the level of patient outcomes: That lowering TPO-Ab titers with selenium meaningfully changes symptoms, thyroid function trajectory, or need for thyroid hormone treatment in Hashimoto's thyroiditis. That selenium supplementation improves fertility outcomes in men with abnormal semen parameters, beyond the biological plausibility of GPx4's role in sperm structure. That routine selenium testing changes outcomes in the general population without a specific clinical indication.

Not established, and worth actively avoiding as a claim: That selenium supplementation prevents cancer in people who are already selenium-replete. Two large randomized trials did not support that use, and one raised a diabetes-risk signal in a post-hoc analysis. Selenium status should not be treated as a general-purpose antioxidant or anti-aging marker to optimize outside a specific clinical question.

If a result is markedly abnormal, especially below 30 mcg/L with cardiac or neurologic symptoms, or above 400 mcg/L with signs of selenosis, that is a reason for prompt clinical evaluation rather than a wait-and-retest approach.